BioDelivery Sciences International Inc. (BDSI) Stock Quote

Detailed Quote for BioDelivery Sciences International Inc. (BDSI) 
$ 2.06   -0.02 (-0.96%) Volume: 152.69 k 3:57 PM EST Feb 3, 2012
Today 5d 1m 3m 1y more
Last Price
2.06
Change $
0.02
Change %
0.96%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
2.07
High
2.10
Low
2.02
Prev Close
2.08
Last Trade
3:57
Volume
152.69 k
52 Wk Hi
4.05
52 Wk Low
0.77
Market Cap
60.9 m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
29,561,655
EPS (TTM)
-1.03
PE Ratio
N/A
Exchange
NSC
News and Media for BioDelivery Sciences International Inc.  (BDSI) 
Sector News | Topic News
News for BDSI
Fri, Jan 06, 2012
6:00 AM Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine - PR Newswire
6:00 AM BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine - PR Newswire
Thu, Dec 29, 2011
2:37 PM ONSOLIS to Benefit from Approval of Class-Wide REMS for All Transmucosal Fentanyl Products - PR Newswire
Tue, Dec 20, 2011
4:22 PM BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study - PR Newswire
Mon, Nov 28, 2011
7:00 AM US Patent Office Rejects All 191 Claims in Key MonoSol Patent Asserted Against BioDelivery Sciences - PR Newswire
Mon, Nov 21, 2011
7:00 AM BioDelivery Sciences to Present at the 23rd Annual Piper Jaffray Healthcare Conference - PR Newswire
Mon, Nov 14, 2011
7:00 AM BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time - PR Newswire
Thu, Nov 10, 2011
7:00 AM BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone - PR Newswire
Mon, Nov 07, 2011
8:58 AM BEMA Fentanyl Submitted for Marketing Authorization in Taiwan - PR Newswire
Tue, Oct 25, 2011
7:00 AM Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors - PR Newswire
Fri, Sep 30, 2011
9:00 AM Global Situation & Resulting Influences - Research Report on BioDelivery Sciences International, Inc. and Watson Pharmaceuticals, Inc. - Marketwire
Wed, Sep 28, 2011
5:16 PM BioDelivery Sciences Announces Results from Phase 3 Efficacy Study for BEMA Buprenorphine in Chronic Pain - PR Newswire
Tue, Sep 06, 2011
7:00 AM BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence - PR Newswire
Wed, Aug 31, 2011
7:00 AM BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences - PR Newswire
Mon, Aug 22, 2011
7:00 AM BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada - PR Newswire
More News for BDSI >>

Tags for BioDelivery Sciences International Inc.

Research stocks or mutual funds related to BioDelivery Sciences International Inc. by keywords or tags. Find companies that have a similar focus to BDSI. The keywords below have been associated to BDSI by either user submission or electronic means.

pain control biotech research pharmaceutical market pharmaceuticals companies generic pharmaceutical pharmaceutical investment european business development pharmaceutical research and development pharmaceutical manufacturing company pharma marketing pharmaceutical industry marketing pharma manufacturing pharma license pharmaceutical supply chain novartis pharmaceuticals active pharmaceutical ingredient pharmaceutical cro active pharmaceutical ingredients pharmaceutical sales pharmaceutical distributors pharma in licensing pharmaceutical development pharmaceutical reports pharmaceutical consultant Drugs pharmaceutical auctions pharmaceutical industry news pharmaceutical manufacturing software pharmaceutical manufacturing pharmaceutical formulation pharmaceutical article contract pharmaceutical pharmaceutical consulting biopharmaceuticals pharmaceutical events pharmaceutical industry pharmaceutical sale pharmaceutical studies pharmaceutical advances pharmaceutical distributor pharmaceutical specialty pharmaceutical out licensing pharmaceutical business development Healthcare pharmaceutical preparation pharmaceutical sector bio pharmaceuticals pharmaceutical innovation sandoz pharmaceuticals pharmaceutical

 

NYE - Equity | NYE - ETF | AMX - Equity | AMX - ETF | NSD - Equity | NSD - ETF
NMF - ETF | NMF - Money Market Fund | NMF - Mutual Fund | OTC - Equity | OTO - Equity | OTO - ETF | OTO - Mutual Fund
CNQ - Equity | CBO - Equity | BDM - Equity | TSX - Equity | TSX - ETF | TSX - Mutual Fund | TSV - Equity | TSV - Mutual Fund

Dow Jones Composite Index | Dow Jones Industrial Avg | Dow Jones Transportation Avg | Dow Jones Utiliy Index | NASDAQ 100
Russell 1000 | Russell 2000 | Russell 3000 | Russell Microcap | Russell Midcap | S&P 500 | S&P MidCap 400 | S&P/TSX 60 | S&P/TSX MidCap

Recently Added Symbols   Firms   Find Financial Advisors

Advisors by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

RIAs by Name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tags: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Insiders: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

All information displayed and available herein is on an "as is", "as available" basis and neither InvestorPoint.com nor any of its underlying service providers, information providers, licensors, employees, distributors or agents make any representations as to the suitability of our service or the materials for any purpose. The information is not intended for trading purposes or advice. We specifically disclaim any representations or warranties, express or implied, including, without limitation, any representations or warranties of merchantability or fitness for a particular purpose. InvestorPoint.com is not an investment adviser. We do not: (a) give investment advice, (b) advocate the purchase or sale of any security or investment and (c) provide, endorse or review any information or data contained herein. We do not guarantee the accuracy of the information and data supplied by information providers. We are not liable or responsible for the quality, accuracy or reliability of this information. You should always seek the assistance of a professional for investment advice.

Copyright © 2010 InvestorPoint.com All rights reserved.